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Abstract Heart failure is a disease characterized by high
prevalence and mortality, and frequent rehospitalizations.
The aim of this study is to investigate the prognostic power
of combining brain natriuretic peptide (BNP) and conges-
tion status detected by bioelectrical impedance vector
analysis (BIVA) in acute heart failure patients. This is an
observational, prospective, and a multicentre study. BNP
assessment was measured upon hospital arrival, while
BIVA analysis was obtained at the time of discharge.
Cardiovascular deaths were evaluated at 90 days by a
follow up phone call. 292 patients were enrolled. Com-
pared to survivors, BNP was higher in the non-survivors
group (mean value 838 vs 515 pg/ml, p\ 0.001). At dis-
charge, BIVA shows a statistically significant difference in
hydration status between survivors and non-survivors [re-
spectively, hydration index (HI) 85 vs 74, p\ 0.001;
reactance (Xc) 26.7 vs 37, p\ 0.001; resistance (R) 445 vs
503, p\ 0.01)]. Discharge BIVA shows a prognostic value
in predicting cardiovascular death [HI: area under the curve
(AUC) 0.715, 95% confidence interval (95% CI)
0.65–0.76; p\ 0.004; Xc: AUC 0.712, 95% CI
0.655–0.76, p\ 0.007; R: AUC 0.65, 95% CI 0.29–0.706,
p\ 0.0247]. The combination of BIVA with BNP gives a
greater prognostic power for cardiovascular mortality
[combined receiving operating characteristic (ROC): AUC
0.74; 95% CI 0.68–0.79; p\ 0.001]. In acute heart failure
patients, higher BNP levels upon hospital admission, and
congestion detected by BIVA at discharge have a signifi-
cant predictive value for 90 days cardiovascular mortality.
The combined use of admission BNP and BIVA discharge
seems to be a useful tool for increasing prognostic power in
these patients.
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Introduction
Despite all available therapies and drugs, acute heart
failure (AHF) incidence remains unacceptably high
worldwide [1]. AHF clinical features are due to the
appearance of signs and symptoms of systemic and pul-
monary congestion [2]. In heart failure, congestion is, at
the same time, a cause and a consequence of worsening
cardiovascular function. The activation of the neurohor-
monal system causes fluid redistribution and accumula-
tion, increases systemic resistance, and reduces
capacitance in large veins, with consequent increased
after load and preload which cannot be tolerated by the
failing heart. These pathophysiological changes lead to
clinical decompensation and to brain natriuretic peptide
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(BNP) release as a consequence of the increased ven-
tricular wall tension [2, 3]. For all these reasons, AHF
treatment is finalized to stop this progressive hemody-
namic course, and as a consequence, decongestion is an
important target in the management of these patients [4].
However, approximately, 50% of patients admitted for
AHF are discharged with persistent signs or symptoms of
congestion [5], and this is of great prognostic significance
considering that the ability to maintain a patient free from
congestion identifies a population with good survival
[6, 7]. The aim of this study is to investigate the ability of
BNP and bioelectrical impedance vector analysis (BIVA)
to identify patients at risk for 90 days cardiovascular
death from hospital discharge.
Materials and methods
This was a prospective observational study in AHF patients
presenting to different Emergency Departments (EDs)
included into the GREAT Network in Italy, Sant’Andrea
University Hospital in Rome, Novara University Hospital,
Padova University Hospital, and in two centers in Brazil
(Fluminense Federal University Department of Cardiology,
and Hospital Unimed Rio, from January 2013 to January
2015.
The inclusion criteria were: ED admission for dyspnea
or symptoms linked to AHF, with expected hospitalization.
Each patient received standard of care according to Euro-
pean Society of Cardiology guidelines [8], and physicians
were blinded to BIVA values. Exclusion criteria were:
psychogenic dyspnoea, post-traumatic dyspnoea, pneu-
mothorax, major surgery, coronary artery disease, ascites,
edema secondary to venous disease, lymphedema,
hypoalbuminemia, body temperature[38 C, amputation
of limbs, burns, patients younger than 18 years, and
patients who were unable to give an informed consent. The
research protocol was reviewed by the human research
Committee from Sant’Andrea Hospital in Rome as coor-
dinating center, and it was consequently approved in all
participating centers. Informed written consent was
obtained from patients before enrollment. The study pro-
tocol conformed to the ethical guidelines of the Declaration
of Helsinki. The final diagnosis of AHF was made
according to recent guidelines [8]. 90 days after hospital
discharge, a telephone call follow up was performed to
evaluate the patient’s follow-up for cardiovascular death.
The aim of this study is to evaluate BIVA and BNP
prognostic value in identifying patients who have more risk
for subsequent death. On the basis of follow-up results, we
divided AHF population into two groups: survivors and
non-survivors.
BIVA evaluation
We used a bioelectrical impedance analyzer, a single
50 kHz frequency (EFG, Akern, Florence, Italy). The
BIVA measurement assessed at the time of patients’ dis-
charges from the hospital was performed at bedside, with
the patient supine, without metal contacts and with inferior
limbs abducted at 45 and superior limbs abducted at 30 to
avoid skin contacts. Four skin electrodes were applied (two
on the wrist and two on the ipsilateral ankle) maintaining a
minimal inter-electrode distance of 5 cm. The device uses
an alternating current flux of 800 lA and an operating
frequency of 50 kHz. The results were visualized in two
ways: as a bivariate impedance vector, or as a BIVA-
derived hydration percentage. The first method includes a
direct impedance plot that measures resistance (R) and
reactance (Xc), as a bivariate vector in a nomogram (R/Xc
graph) [9]. Reference values [10, 11], stratified for classes
of age, BMI, and gender are plotted as tolerance ellipses in
the same coordinate system. Reference intervals are plotted
as three tolerance ellipses, and are distinguished corre-
sponding to the 50th, 75th, and 95th vector percentile of the
healthy reference population [11, 12]. The major axis of
this ellipse indexes hydration status, and the minor axis
reflects tissue mass. The second method expresses the state
of hydration as a percentage called hydration index (HI)
[12]. This value is calculated by an independently deter-
mined equation that uses the two components of BIVA, R
and Xc. HI normal value is between 72.7 and 74.3%,
corresponding to the 50th percentile [12, 13]. At discharge,
R and Xc were recorded for each patient, normalized by the
subject’s height and graphically expressed on the R–Xc
plane; furthermore, HI was also assessed.
BNP assessment
A blood sample for BNP was performed for all patients
upon arrival in the ED through an EDTA anticoagulated
whole blood test tube. The sample was then sent to the
central laboratory where a quantitative chemiluminescent
immunoassay (Architect BNP by Abbott) was used to
measure BNP in plasma.
hs-cTnI assay
Samples of peripheral venous blood were drawn in each
patient, in 10 cc heparinized tubes, and then sent to our
central hospital laboratory as hs-cTnI was measured.
Indeed, a routine screening diagnostic test was performed
in real time for the detection of an acute coronary syn-
drome. The ARCHITECT STAT High Sensitive Troponin-
I assay (Abbott Laboratories, Abbott Park, Illinois, USA) is
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a chemiluminescent microparticle immunoassay for the
in vitro quantitative determination of cardiac troponin I,
and can be used with the Abbott ARCHITECT i2000SR
and i1000SR analysers [14]. Results are available within
16 min. ARCHITECT STAT High Sensitive Troponin-I
assay can detect troponin I in 96% of the reference popu-
lation, and has a recommended 99th percentile cut-off of
26.2 pg/ml. The manufacturer’s instructions for use also
state a 99th percentile cut-off of 34.2 pg/ml for men and
15.6 pg/ml for women [15].
Statistical analysis
Continuous variables were expressed as mean ± SD if
normally distributed, or median (interquartile range—IQR)
if not normally distributed, unless otherwise specified, and
the appropriate parametric (t test) or nonparametric (Mann–
Whitney) test was used to assess significance of the differ-
ences between subgroups. Categorical variables were dis-
played as frequencies and compared using the v2 test. All of
the tests were two-sided and statistical significancewas set at
p\ 0.05. BIVA data were analyzed as R/Xc graph using
BIVA software by Piccoli A. and Pastori G. Univariate
analysis was performed to evaluate the predictive perfor-
mance of BIVA variables and of clinical signs and odds ratio
(OR) and 95% confidence intervals (95% CI) were calcu-
lated. Multivariate survivor analysis was performed with
Cox analysis. Receiver operating characteristics (ROC)
curves analysis was performed to identify the prognostic
value of clinical variables and BIVA variables alone or in
combination. All data were first analyzed for normality of
distribution using the Kolmogorov–Smirnov test of nor-
mality. Statistical analysis was performed using the Statis-
tical Package for Social Science (SPSS), release 15.0.
Results
292AHF patients were included into the study. The patients’
characteristics are shown in Table 1. At 90 days, 36 patients
had died (12%). The age, the presence of rales, levels of Hs
Troponin I, BNP, and BIVA variables, show statistically
significant differences between survivors and non-survivors.
BNP levels are higher in the non-survivor group than in
survivors (respectively, 838 vs 512 pg/ml, p\ 0.01). BIVA
values performed at discharge, show a significant presence of
congestion in patients who die [median values in non-sur-
vivors vs survivors, respectively, HI 85–74% (p\ 0.001),
R 445–503 Ohm/m (p\ 0.01), Xc 26.7–37 Ohm/m
(p\ 0.0001)]. As shown in Table 2, at univariate analysis,
BIVA and BNP are significantly associated with 90 days
mortality. At multiple regression analysis, only age and BNP
maintain statical significance (Table 2). ROC analysis
shows that BIVA is a predictor of death [(HI:AUC 0.71, 95%
CI 0.65–0.76, p\ 0.004); (Xc: AUC 0.71, 95% CI
0.655–0.76, p\ 0.007); (R: AUC 0.65, 95% CI 0.29–0.706,
p\ 0.02)], while BNP does not reach statistical significance
(AUC 0.55, 95% CI 0.497–0.615, p = 0.42), as shown in
Table 1 Patients’ characteristics
Variables Non-survivors (36/292 pts) 12.3% Survivors (256/292 pts) 87.6% p
Age years (median) 83.50 (76.50–87.50) 76.00 (65.00–83.00) 0.0002
Gender M/F 16/20 119/137 0.85
Rales y/n 30/6 148/108 0.003
Edema y/n 28/8 164/91 0.13
JVD y/n 20/16 109/146 0.15
SBP mmHg (median) 132.50 (120.00–147.50) 127.50 (110.00–150.00) 0.76
DBP mmHg (median) 75.00 (62.50–80.00) 70.00 (65.00–80.00) 0.81
HR bpm (median) 83.50 (70.00–95.50) 78.00 (68.00–90.00) 0.13
BNP pg/ml (median) 838.50 (371.00–1295.00) 512.50 (282.50–956.50) 0.01
Hydration index % (median) 85.00 (74.02–87.95) 74.00 (73.42–81.15) 0.001
R Ohm/m (median) 445.30 (360.80–521.97) 503.60 (433.15–566.55) 0.01
Xc Ohm/m (median) 26.70 (20.75–37.15) 37.00 (30.20–47.40) 0.0001
Creatinine m g/dl (median) 1.40 (1.01–2.21) 1.19 (0.90–1.60) 0.058
Na mmol/L (median) 138.00 (131.50–142.00) 138.00 (135.00–140.00) 0.83
Tpl pg/ml (median) 0.076 (0.030–0.19) 0.030 (0.020–0.080) 0.0007
Variables are presented as median (interquartile range)
Variables statistically significant between non-survivor and survivor group are indicated in bold (age, rales, BNP, HI, R, Xc, TpI)
y/n yes/no, JVD jugular vein distension, SBP systolic blood pressure, DBP diastolic blood pressure, mmHg millimeters of mercury, HR heart rate,
bpm beats per minute, pg/ml picograms per millimeter, BNP brain natriuretic peptide, % percentage, R resistance, Xc reactance, Ohm/m Ohm
meter, Na sodium, mmol/l millimoles per liter, TpI Troponin I
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Fig. 1. However, combining BIVA (expressed as hydration
index) with BNP (Fig. 2), we obtain the best prognostic
value (AUC 0.73, 95% CI 0.682–0.788, p\ 0.0001).
Discussion
BIVA and BNP are currently considered both valid
instruments in the management of AHF patients [16–20].
They reflect two aspects of the same pathophysiological
mechanism: BNP is released as a result of the increased
ventricular filling pressure and ventricle’s wall tension,
while BIVA variables reflect the body hydration changes in
the failing cardiovascular system [3, 18]. For these reasons,
it is currently well known that in AHF patients, BIVA,
BNP, NYHA functional classes and central venous pres-
sure are strongly related [16, 20].
In our study, 90 days non-survivor AHF patients have
higher BNP values upon ED arrival, suggesting that BNP at
the moment of patient presentation could be very useful in
the risk stratification for these patients. The prognostic
validity of wBNP measurement has been previously eval-
uated. Nishii et al. report that high levels of BNP are
predictor of long term risk in patients with non ischemic
dilated cardiomyopathy [21]. In the Italian Red Study [22],
BNP serial evaluation (at admission, at 24 h, and at dis-
charge), were performed in 247 AHF patients. At admis-
sion, similar to our results, BNP median value was 822 pg/
ml. A reduction of BNP levels during hospitalization,
demonstrates a strong negative prognostic value for future
cardiovascular outcomes. In addition, from a study sub-
analysis, it was shown that serial BNP evaluation after
discharge in chronic AHF elderly patients is useful in the
prediction of 30 days post discharge events [22]. In par-
ticular, the gradual and continuous decrease of BNP after
hospital discharge in that study is associated with a lower
incidence of adverse events.
Oremus et al. in a recent review of the literature [3]
show that BNP is associated with all-cause mortality and
composite outcomes in both decompensated and chronic
stable HF population. Nevertheless, in the literature there is
limited evidence that BNP adds incremental value to other
Table 2 Univariate and
multiple regression analysis
Univariable model
result variables
B OR (95% CI) p
Age 0.061 ± 0.019 1.06 (1.02–1.10 ) 0.001
Gender -0.082 ± 0.358 0.92 (0.45–1.85) 0.81
DBP -0.005 ± 0.013 0.99 (0.96–1 02) 0.65
SBP -0.0007 ± 0.006 0.99 (0.98–1.01) 0.91
HR 0.010 ± 0.008 1.01 (0.99–1.02) 0.18
Na 0.007 ± 0.037 1.00 (0.93–1.08) 0.83
Tpl 0.238 ± 0.127 1.26 (0.98–1.62) 0.06
BNP 0.0004 ± 0.0001 1.00 (1.00–1.00) 0.005
Creatinine 0.127 ± 0.136 1.13 (0.87–1.48) 0.34
Hydration index 0.120 ± 0.028 1.12 (1.06–1.19) <0.0001
R -0.004 ± 0.001 0.99 (0.99–0.99) 0.01
Xc 0.063 ± 0.017 0.93 (0 90–0.97) 0.0004
JVD 0.515 ± 0.358 1.67 (0.82–3.38) 0.15
Leg edema 0.663 ± 0.421 1.94 (0.84–4.43) 0.11
Rales 1.294 ± 0.464 3.64 (1.46–9.07) 0.005
Multiple regression Variables B SE p OR (95% CI)
Age 0.057983 0.023727 0.01 1.05 (1.01–1.11)
BNP 0.00044843 0.00019086 0.01 1.00 (1.00–1.00)
Hydration index 0.10045 0.064278 0.1181 1.10 (0.97–1.25)
R -0.0018949 0.0023390 0.4179 0.99 (0.99–1.00)
Xc 0.0041397 0.032232 0.8978 1.00 (0.94–1.06)
Rales 0.48071 0.52555 0.3604 1.61 (0.57–4.53)
Constant -14.5207
Statistically significant variables at univariable analysis (age, BNP, HI, R, Xc, rales) and multiple
regression (age, BNP) are shown in bold
JVD Jugular vein distension, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, BNP
brain natriuretic peptide, R resistance, Xc reactance, Na sodium, TpI Troponin I
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prognostic factors in predicting all-cause and cardiovas-
cular mortality in the short and long terms. Instead, in our
study BNP is been more predictive of death when used in
combination with BIVA (Fig. 2).
As for BIVAvariables at discharge, our study confirms that
some HF patients are discharged with a persistent state of
congestion. Their identification becomes crucial because
these patients are thosewith a higher risk for 90 daysmortality
[6, 7]. In the DOSE-AHF trial, there exists a correlation
between weight loss, net fluid loss and 60th days death or
rehospitalization [4]. In detecting congestion and latent fluid
overload, BIVA has greater diagnostic sensitivity than other
techniques (including fluid balance), and it also shows an
emerging role for its prognostic value [16]. Previous data from
our group demonstrates that the reduction of congestion
detected by BIVA, during AHF patients hospitalization, is
linkedwith an improvement in patients’ outcome [17, 20, 23].
In particular, we demonstrate that BIVA values at arrival in
the ED are very useful in identifying patients at high risk for
death and hospitalization at short and long term [20]. The
same result is shown by Donner Alves et al. who describe the
progressive changes in hydration status during diuretic ther-
apy in AHF hospitalized patients [24]. Instead, in this study,
we evaluate BIVAprognostic relevance before discharge; this
Fig. 1 BNP and BIVA ROC curves for the predication of death at 90 days. R: AUC 0.65, 95% CI 0.29–0.706, p\ 0.0247; Xc: AUC 0.712, 95%
CI 0.655–0.76, p\ 0.007; HI: AUC 0.715, 95% CI 0.65–0.76, p\ 0.004; BNP: AUC 0.557, 95% CI 0.497–0.615, p = 0.42
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was done assuming that at this moment, clinical signs of
congestion are often missing as a consequence of diuretic
therapy, and clinical judgment may not be reliable. In this
perspective, this study adds important information: BIVA
analysis is important because it allows identification of those
patients who have subclinical congestion, and this could help
physician in the decision of patient’s discharge.
In addition, our data confirm the utility of BNP in the
risk stratification of AHF patients arriving to the ED, but
the most important and newest aspect is derived from the
combined use of BNP and BIVA.
In a previous study from our group, we find that BNP
and BIVA may be very helpful in the diagnosis, but also
during the therapeutic management of AHF patients,
maintaining an optimal hydration status through the correct
use of diuretics [13]. This study extends these findings
demonstrating that when AHF patients are discharged with
a persistent congestive state, even if clinically latent, they
will have a worse outcome.
The most important limitation of this study is the lack of
information about the type of heart failure (with preserved
ejection fraction or not), and the likely presence of
comorbidities due to the population’s median age that
makes the sample inhomogeneous.
Conclusion
Our study shows that in AHF patients, a high BNP level at
admission allows accurate risk stratification. Moreover, at
the time of discharge, it is necessary to achieve an optimal
hydration status detected by BIVA. The achievement of
normal hydration detected by noninvasive assessment of
body fluid content by BIVA at discharge, should be one of
the major targets in the management of AHF patients to
improve their life expectancy. The combined use of BIVA
and BNP in AHF patients should be a complementary
instrument in the management of AHF patients, to identify
patients at high risk of death in the next 90 days after
hospital discharge.
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